Menopause and Hormone Therapy: The Long Version

Perimenopause is the part that resists measurement

Menopause is a single day, identified in hindsight: twelve consecutive months with no period. Everything people call “menopause symptoms” mostly happens before it, during the transition into it, and that transition commonly runs for several years while cycles are still arriving. The average final period lands somewhere around the early fifties, with wide individual variation, and the years leading up to it are the ones that get missed.

The reason they get missed is that perimenopause is a clinical diagnosis, made on the pattern of symptoms, age and cycle history rather than on a lab value. Hormone levels in the transition do not decline in an orderly line — they swing, sometimes higher than they ever were in a regular cycle, sometimes low, and they can do both in the same month. A single blood draw on a single morning can come back entirely unremarkable in someone who is plainly unwell.

That is not an argument against testing. It is an argument about what testing is for. Thyroid dysfunction, iron deficiency and vitamin B12 deficiency all overlap heavily with the transition, all are common in this age group, and all are more treatable than the transition itself. A panel is there to find those and to start the record — not to prove perimenopause, which it cannot do. When in your cycle to test hormones covers the timing question, and what perimenopause actually does covers the symptom picture in more detail than this page has room for.

The symptom picture is much wider than hot flashes

Vasomotor symptoms — hot flashes and night sweats — are the ones with the name, and for some people they genuinely are the worst of it. But they are not usually the thing that stops a working week working.

Sleep is the most common complaint that does not get attributed to the transition: waking in the small hours and staying awake, with or without heat attached to it. Mood changes in a particular way — irritability out of proportion to the trigger, and anxiety that arrives without a subject, which is harder to argue with than anxiety about something. Cognition shows up as word-finding difficulty and reduced concentration; it is real, it is measurable in research settings, and for most people it does not persist indefinitely. Joints ache, often first thing, often in the hands and shoulders, and the connection to estrogen is rarely made. Skin and hair change texture and density. Digestion slows. Weight redistributes toward the middle, which is a different phenomenon from simply gaining.

And then the genitourinary symptoms, which belong in a category of their own and get one further down this page, because unlike everything above they do not settle with time.

Almost every item on that list is routinely put down to stress, workload, or being 49. Sometimes that is correct. It is worth establishing which, because the attribution tends to be made once and then never revisited.

How the decision to start is actually made

There is no threshold that triggers hormone therapy. No number on a panel says “start”, which surprises people who expect medicine to work the way a blood pressure reading does. The decision is a weighing, and it runs on four inputs.

What the symptoms are costing you. This is the largest input and the one only you can supply. Hot flashes that are a nuisance and hot flashes that have destroyed your sleep for two years are the same symptom and a completely different calculation.

Where you are in time. How old you are, and how long since your final period. This is the input most people do not know matters, and it is covered in the next section.

Your history. A personal history of breast cancer, of blood clots, of stroke or certain cardiovascular conditions, of unexplained bleeding, or of liver disease changes the answer — sometimes to no, more often to a different route or a different conversation. Migraine with aura, high blood pressure and a family history of clotting all matter without necessarily ruling anything out.

What the alternatives look like for you. Non-hormonal options exist for vasomotor symptoms, sleep and mood, and for some people they are the right first move.

What that adds up to is a conversation, not a test result. How to tell whether hormone therapy is worth discussing is the article to read before that appointment, and Who should not take hormone therapy sets out the histories that genuinely change the answer.

The risk evidence, and how it got taught wrong

In 2002 the Women's Health Initiative stopped one arm of a large randomized trial early and announced an increased risk of breast cancer in women taking estrogen together with a synthetic progestin. The finding was real. What happened next was a failure of communication with consequences that lasted two decades: the result was reported almost entirely in relative terms, prescriptions collapsed worldwide, and a generation of clinicians was trained to say no by default.

Two things about that trial matter more than anything else. The first is who was in it. The average participant was in her early sixties, and most were more than a decade past their final period — a population chosen to study heart disease prevention, not the women in front of a clinician with disrupted sleep at 51. The second is what the absolute numbers were. Expressed as cases rather than percentages, the increase in the combined arm amounted to well under one additional breast cancer per thousand women per year.

That is not nothing, and it is not a reason to dismiss the finding. It is a reason to hold it at the right size. A risk of that magnitude belongs in the same conversation as the other everyday exposures a person already weighs without panic, and it is weighed against what the symptoms are costing — which is exactly the calculation the relative framing made impossible.

The two arms were not the same. The trial also ran an estrogen-alone arm, in women who had had a hysterectomy, and it did not show the same breast cancer signal. Long-term follow-up of that group has been reported as showing fewer breast cancers rather than more. Estrogen with a progestogen and estrogen alone are different exposures with different risk profiles, and treating them as one thing called “HRT” is a large part of how the record got garbled.

What has followed is the timing hypothesis: that starting closer to the transition produces a materially better balance than starting many years after it. The evidence has pointed consistently in that direction, and in February 2026 the FDA removed the boxed warnings for cardiovascular disease, breast cancer and probable dementia from menopausal hormone therapy products, pointing to randomized evidence in women who start within roughly ten years of menopause.

None of which makes hormone therapy risk-free or right for everyone. It means the conversation can now be proportionate to the evidence rather than closed by a warning that applied one blanket caution to every woman and every formulation. Hormone therapy and a history of blood clots and Hormone therapy when you get migraines deal with the two histories that come up most.

Why the route of delivery is not a detail

Estrogen taken by mouth and estrogen absorbed through the skin do not behave the same way, and the difference is not convenience. Anything swallowed passes through the liver before it reaches the rest of the body, and that first pass changes the production of several clotting factors and binding proteins. Estrogen delivered through the skin — a patch, a gel, a cream — largely bypasses it.

The practical consequence is that the clot risk associated with oral estrogen is not automatically carried over to transdermal estrogen. Observational evidence has consistently suggested little or no increase with the transdermal route, and guidelines increasingly treat it as the preferred option where clot risk is a consideration at all. It is observational rather than randomized evidence, which is worth knowing when you hear it stated as a certainty.

Beyond that, routes differ in how steady the delivery is, how much of a say you have over adjustment, how visible they are, and how they behave with skin sensitivity or heat. There is no single best answer; Estradiol Patch or Pill: How the Two Routes Differ and Estrogen Cream or Patch: What Changes Between Them lay out the trade-offs.

What progesterone is actually for

This is the most widely misunderstood part of a hormone therapy plan. If you have a uterus and you take estrogen, you need a progestogen alongside it — not to balance your mood or to complete a set, but because unopposed estrogen stimulates the endometrium and that stimulation carries a real risk of endometrial cancer over time. Endometrial protection is the job. Any other benefit is secondary to it.

It follows that if you have had a hysterectomy, the usual reason for taking it is gone — which is what Do You Need Progesterone After a Hysterectomy? works through, including the situations where it is still considered.

The other distinction worth carrying is that progestin and progesterone are not the same molecule. Micronized progesterone is structurally identical to what the body makes; the synthetic progestins are a family of different compounds with different effects, and the progestin used in the WHI combined arm is one specific member of that family rather than a stand-in for all of them. Some evidence suggests the breast signal differs between them. It is not conclusive, and it should not be presented as though it were. Progestin and Progesterone Are Not the Same Thing is the full version.

The symptoms that do not resolve on their own

Vaginal dryness, discomfort or pain with sex, urinary urgency and recurrent urinary tract infections make up what is now called the genitourinary syndrome of menopause. They sit in a different category from hot flashes for one reason: hot flashes tend to settle over years; these do not. Left untreated they typically persist and slowly worsen, and they are also the symptoms least likely to be raised in a ten-minute appointment — which is a poor reason for them to go untreated for a decade.

They also respond well to treatment applied locally. A vaginal estrogen preparation acts where it is placed, and the amount reaching the rest of the body is very small compared with a systemic preparation — which is why it is a different conversation from systemic hormone therapy, with a different risk discussion, and why it can often be used by people for whom systemic therapy is not the right answer.

That includes, for many people, a history of breast cancer: guidance in that situation has moved considerably, and it is a decision made with the oncology team rather than around them. Vaginal Estrogen After Breast Cancer: What the Guidance Says and What vaginal estrogen does cover the detail. Non-hormonal moisturizers and lubricants help with comfort and are worth using regardless; they do not change the underlying tissue.

What hormone therapy will not fix

A guide that only lists benefits is a brochure. Some honest limits.

It is not a weight loss treatment. The redistribution of body fat through the transition is driven by several things at once, and hormone therapy is not reliably one of the levers. It does not generally cause weight gain either, which is the more common fear — Does hormone therapy cause weight gain? goes through what the trial data shows.

It is not a treatment for depression, although mood symptoms tied to the transition often improve. A depressive illness needs treating as one.

It is not a dementia preventive. It is not prescribed for cognitive protection, and anyone selling it on that basis is ahead of the evidence.

It does not undo everything the transition changed. Bone density, cardiovascular risk markers and the shift in cholesterol all move through midlife for reasons that are only partly hormonal, and sleep, training, alcohol and stress keep their votes.

It does not work instantly. Vasomotor symptoms typically respond within weeks; sleep, mood and genitourinary symptoms run on their own timelines, and the tissue changes are the slowest of all. How long hormone therapy takes to do anything is more specific than we can be here.

How long people stay on it

The old advice was the shortest duration at the smallest amount that worked, and a hard stop somewhere around five years or a birthday. That rule has not survived contact with the evidence. Current position statements from the major menopause societies do not set an arbitrary age or duration limit; they describe an ongoing, periodic reassessment of benefit against risk, which will read differently at 52 and at 68.

In practice that means a review at least yearly, in which the reasons for continuing are restated rather than assumed. Some people stop after a couple of years because the symptoms that took them there have gone. Some continue for much longer with a clear reason each time. Genitourinary treatment often continues indefinitely, because the symptom returns when it stops.

Stopping is its own event and is worth planning rather than improvising — What happens when you stop hormone therapy sets out what to expect. And it is worth saying plainly that starting later is not the same as being disqualified; Is it ever too late to start? is an honest answer to the question most people ask at 60.

Frequently asked questions